| gap-pubmed-20260410- | Why does Tyro3 deficiency not affect neuroinvasive viral susceptibility unlike M | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms mediate Mertk-interferon-β synergy in blood-brain barr | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do TAM receptors protect against neuroinvasive viruses despite their known i | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Do senescent cells contribute differently to various neurodegenerative diseases? | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which specific non-neuronal cell types become senescent in the aging brain? | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific mechanisms by which senescent cell SASP factors cause neur | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ESCRT-mediated phagophore sealing mechanistically differ between PARKIN | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine the different CHMP4B residence times between | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do disease-related gene expression patterns in NGN2 neurons compare to those | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurological-disease-modeling |
| gap-pubmed-20260410- | What specific molecular mechanisms coordinate the multiple pathways driving neur | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuronal-development |
| gap-pubmed-20260410- | How do RIPK1's molecular patterns and codon bias influence neuroinflammation and | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms underlie RIPK1's dramatically different expression between corte | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can membrane trafficking pathways be therapeutically exploited for effective | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms connecting Aβ toxicity and tau pathol | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does metformin show therapeutic potential in PD when it primarily targets me | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do STAT3, FYN, and BECN1 mechanistically drive rapid PD progression? | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link CSF P-tau/α-synuclein ratio to distinct PD progression rate | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific challenges prevent surgical gene therapy from translating preclini | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do AAV-based gene therapies succeed in infants but fail to achieve safe CNS | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the MYBBP1A-p53-TPPII-SIRT6/7-CD147 subclusters mechanistically control W | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms explain how PIN7 network disruption causes similar age | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does hippuric acid show higher affinity for GPR109A versus GPR109B despite s | open | 0.72 | 0.00 | 2026-04-10 | 0 | | structural-biology |
| gap-pubmed-20260410- | How does GPR109A-hippuric acid binding mechanistically regulate osteoclastogenes | open | 0.77 | 0.00 | 2026-04-10 | 0 | | metabolic-signaling |
| gap-pubmed-20260410- | How can sleep/circadian alterations be validated as reliable early biomarkers ac | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link melatonin, orexin, and MCH dysfunction to neurode | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does BubR1 deficiency cause the observed reduction in oligodendrocyte progen | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link BubR1 mitotic checkpoint function to oligodendroc | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do multiple aging mechanisms interact to drive neurodegeneration versus syst | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the reversibility threshold for aging phenotypes in neurodegener | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do neurons specifically regulate this indirect BH3-Bcl-2 apoptotic pathway c | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the precise molecular mechanism by which BH3-only proteins engage multip | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do ongoing debates persist about water transport mechanisms across membranes | resolved | 0.68 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-pubmed-20260410- | What are the molecular mechanisms by which cotransporters mediate water transpor | resolved | 0.77 | 0.00 | 2026-04-10 | 0 | | cellular-neuroscience |
| gap-pubmed-20260410- | Why is CXCL10 specifically predictive of CPSP risk compared to other inflammator | open | 0.74 | 0.00 | 2026-04-10 | 0 | | pain-biomarkers |
| gap-pubmed-20260410- | How does rTMS modulate CXCL10 levels and what is the causal relationship to pain | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific neural mechanisms by which DLPFC rTMS prevents chronic pai | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | pain-neuroscience |
| gap-pubmed-20260410- | What determines the tissue-specific targeting patterns in MOG vs AQP4 antibody-m | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do AQP4-seronegative NMOSD cases show distinct clinical features like bilate | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Does early ERT intervention prevent or delay neurodegeneration in ASMD patients | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms determine the critical window for preventing irreversible growth | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which gene delivery system (LPD vs AAV) provides superior therapeutic efficacy f | open | 0.79 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-pubmed-20260410- | What mechanisms link ASPA enzyme deficiency to spongiform brain degeneration in | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do LRRK2 carriers and non-LRRK2 PD patients show similar phenotypes despite | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the bona fide physiological substrates of LRRK2 kinase activity? | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do LRRK2 kinase inhibitors affect its non-kinase functions and self-regulato | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can cognitive impairments after stroke be measured more accurately and compr | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neuropsychological-assessment |
| gap-pubmed-20260410- | What mechanisms drive cognitive recovery after stroke and how can they be valida | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroplasticity |
| gap-pubmed-20260410- | What are the specific pathophysiological mechanisms underlying cognitive symptom | open | 0.78 | 0.00 | 2026-04-10 | 0 | | stroke-neurobiology |
| gap-pubmed-20260410- | What determines the temporal sequence between AMPK inhibition and mitochondrial | open | 0.75 | 0.00 | 2026-04-10 | 0 | | mitochondrial-biology |
| gap-pubmed-20260410- | How does aconitine-induced mitochondrial dysfunction translate to neurodegenerat | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |